NCT07609576 Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
| NCT ID | NCT07609576 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Infanta Leonor University Hospital |
| Condition | Lymphoma Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2026-05-14 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2026-05-14 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies. Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies. 2. Patients must have initiated BsAb therapy within 30 days prior to study enrollment. 3. Ability to provide informed consent. 4. Severe infections will be recorded the first year, but infectious events past confirmed relapse or new treatments for the underlying disease will not be recorded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07609576 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07609576 currently recruiting?
Yes, NCT07609576 is actively recruiting participants. Contact the research team at mariastefania.infante@salud.madrid.org for enrollment information.
Where is the NCT07609576 trial being conducted?
This trial is being conducted at Madrid, Spain, Madrid, Spain.
Who is sponsoring the NCT07609576 clinical trial?
NCT07609576 is sponsored by Infanta Leonor University Hospital. The trial plans to enroll 350 participants.